# OnCo record paper-keynote-a18-pfs-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-a18-pfs-lancet-2024" ;
  schema:name "KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)"@en ;
  schema:description "Adding pembrolizumab to standard chemoradiotherapy for high-risk locally advanced cervical cancer reduced progression or death by 30%, the first systemic advance in this setting since cisplatin was added to radiotherapy in 1999."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00317-9>, <https://pubmed.ncbi.nlm.nih.gov/38521086/>, <https://clinicaltrials.gov/study/NCT04221945> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)00317-9> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Lorusso D, Xiang Y, Hasegawa K, et al." ;
  onco:cancers <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/gemelli/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/standard-of-care/> ;
  onco:trials <https://onco.cc/trials/keynote-a18/> ;
  onco:people <https://onco.cc/people/domenica-lorusso/>, <https://onco.cc/people/giovanni-scambia/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/lancet/> .